Ferry, D R <br/><br/>
A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Sep 2000 
 - 1165-70 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0923-7534 
<br/><br/><label>Standard No.: </label>10.1023/a:1008303715515  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacokinetics<br/>Benzoquinones--pharmacokinetics<br/>Disease Progression<br/>Disease-Free Survival<br/>Drug Evaluation<br/>Female<br/>Humans<br/>Linoleic Acid--blood<br/>Lipoxygenase Inhibitors--pharmacokinetics<br/>Male<br/>Middle Aged<br/>Pancreatic Neoplasms--drug therapy<br/>Thromboxane B2--antagonists & inhibitors